drugset

drugset / Trial / NCT00833638

A Study in Erectile Dysfunction

NCT00833638 ↗

Phase 4 Completed 372 enrolled Eli Lilly and Company

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the day of onset of efficacy of tadalafil dosed once-a-day.

Timeline

Start: 2009-02
Primary completion: 2009-06
Completion: 2009-06

Outcome

Met primary endpoint

registry analysis (superiority or other test); Tadalafil 5 mg vs Placebo; p = 0.006; Regression, Logistic; NCT00833638 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tadalafil	Small molecule	5 mg	Oral

Indications